EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

US CNS Disorders Drug Pipeline Insight 2014

  • ID: 2931017
  • Drug Pipelines
  • August 2014
  • Region: United States
  • 1700 Pages
  • PNS Pharma
1 of 4

FEATURED COMPANIES

  • Alkermes
  • AstraZeneca
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Novartis
  • Roche
  • MORE
The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market.

Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer’s markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each.

New technology including advancements in stem cell therapy and of nanotechnology is expected to drive the growth of the CNS market. Nanotechnology in the form of the nanomaterials for wound care, drug delivery and immunomodulation is specifically seen as a positive influence on CNS therapy that is expected to open growth opportunities. While each of these therapeutic subcategories are served by established treatments there are certain markets segments with significant unmet medical needs still remain, indicating potential in these areas. There are newer treatment methodologies under development such as that using stem cell therapy and of nanotechnology that seek to address these opportunities.

The rapid advances in the R&D segment, many novel drugs are currently available for the treatment of CNS disorders. Industry related to CNS drug delivery system has also got a boost due to rapid advancement of CNS disorders market. Given the magnitude of number of patients and demand for better drugs is going to push pharmaceutical companies for significant investments. Changing life-style is one the main contributor of CNS disorders in US. Increased longevity and ageing population along with launch of novel drugs will drive the growth of CNS disease market in future.

US CNS Disorders Drug Pipeline Insight 2014 Report Highlight:

- Market Overview & Incidence by Disease
- CNS Disorder Market Dynamics
- CNS Disorder Pipeline by disease, Phase & Company
- CNS Disorder Pipeline: 1083 Drugs in Pipeline
- Majority CNS Drugs in Preclinical Phase: 396 Drugs
- Majority CNS Drugs for Neurodegenerative Disorders: 228 Drugs in Pipeline
- CNS Disorder Market Drugs: 109 Drugs
- Majority CNS Drugs Marketed for Epilepsy: 24 Drugs

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alkermes
  • AstraZeneca
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Novartis
  • Roche
  • MORE
1. Introduction to Central Nervous System (CNS) Disorder

2. US Central Nervous System (CNS) Disorder Market Overview
2.1 Market Overview
2.2 Clinical Pipeline Insight

3. US Central Nervous System (CNS) Disorder Incidence by Disease
3.1 Alzheimer's Disease
3.2 Multiple Sclerosis
3.3 Epilepsy
3.4 Parkinson Disease
3.5 Migraine
3.6 Huntington's disease
3.7 Schizophrenia
3.8 Anxiety
3.9 Insomnia
3.10 Bipolar Disorder
3.11 ADHD

4. US Central Nervous System (CNS) Disorder Market Dynamics
4.1 Favorable Market Parameters
4.2 Market Challenges
4.3 Future Growth Opportunity

5. US Multiple CNS Disorder Drug Pipeline by Phase & Company
5.1 Clinical Pipeline Insight by Phase & Company
5.2 Marketed Drugs Clinical Profile

6. US Alzheimer's Disease Drug Pipeline by Phase & Company
6.1 Clinical Pipeline Insight by Phase & Company
6.2 Marketed Drug Clinical Profile

7. US Multiple Sclerosis Drug Pipeline by Phase & Company
7.1 Clinical Pipeline Insight by Phase & Company
7.2 Marketed Drug Clinical Profile

8. US Parkinson's Disease Drug Pipeline by Phase & Company
8.1 Clinical Pipeline Insight by Phase & Company
8.2 Marketed Drug Clinical Profile

9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company
9.1 Clinical Pipeline Insight by Phase & Company
9.2 Marketed Drug Clinical Profile

10. US Epilepsy Drug Pipeline by Phase & Company
10.1 Clinical Pipeline Insight by Phase & Company
10.2 Marketed Drug Clinical Profile

11. US Migraine Drug Pipeline by Phase & Company
11.1 Clinical Pipeline Insight by Phase & Company
11.2 Marketed Drug Clinical Profile

12. US Huntington's Disease Drug Pipeline by Phase & Company
12.1 Clinical Pipeline Insight by Phase & Company
12.2 Marketed Drug Clinical Profile

13. US Neuropathic Pain Clinical Pipeline by Phase & Company
13.1 Clinical Pipeline Insight by Phase & Company
13.2 Marketed Drug Clinical Profile

14. US Schizophrenia Clinical Trial Insight by Phase & Company
14.1 Clinical Pipeline Insight by Phase & Company
14.2 Marketed Drug Clinical Profile

15. US Sleep Disorders Drug Pipeline by Phase & Company
15.1 Clinical Pipeline Insight by Phase & Company
15.2 Marketed Drug Clinical Profile

16. Competitive Landscape
16.1 Alkermes
16.2 Allergan
16.3 AstraZeneca
16.4 Biogen Idec
16.5 Bristol-Myers Squibb
16.6 Eli Lilly
16.7 GlaxoSmithKline
16.8 Merck
16.9 Novartis
16.10 Pfizer
16.11 Roche
16.12 Sanofi
16.13 Sunovion Pharmaceuticals
16.14 Teva Pharmaceutical

List Of Figures:

Figure 2-1: US - CNS Disorders Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-2: US - CNS Disorders Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-3: US - CNS Disorder Drugs Clinical Pipeline by Disease (%), 2014
Figure 2-4: US - CNS Disorder Drugs Clinical Pipeline by Disease (Number), 2014
Figure 2-5: US - CNS Disorder Drugs in Research Phase by Disease (%), 2014
Figure 2-6: US - CNS Disorder Drugs in Research Phase by Disease (Number), 2014
Figure 2-7: US - CNS Disorder Drugs in Preclinical Phase by Disease (%), 2014
Figure 2-8: US - CNS Disorder Drugs in Preclinical Phase by Disease (Number), 2014
Figure 2-9: US - CNS Disorder Drugs in Clinical Phase by Disease (%), 2014
Figure 2-10: US - CNS Disorder Drugs in Clinical Phase by Disease (Number), 2014
Figure 2-11: US - CNS Disorder Drugs in Phase-0 by Disease (%), 2014
Figure 2-12: US - CNS Disorder Drugs in Phase-0 by Disease (Number), 2014
Figure 2-13: US - CNS Disorder Drugs in Phase-I by Disease (%), 2014
Figure 2-14: US - CNS Disorder Drugs in Phase-I by Disease (Number), 2014
Figure 2-15: US - CNS Disorder Drugs in Phase-I/II by Disease (%), 2014
Figure 2-16: US - CNS Disorder Drugs in Phase-I/II by Disease (Number), 2014
Figure 2-17: US - CNS Disorder Drugs in Phase-II by Disease (%), 2014
Figure 2-18: US - CNS Disorder Drugs in Phase-II by Disease (Number), 2014
Figure 2-19: US - CNS Disorder Drugs in Phase-II/III by Disease (%), 2014
Figure 2-20: US - CNS Disorder Drugs in Phase-II/III by Disease (Number), 2014
Figure 2-21: US - CNS Disorder Drugs in Phase-III by Disease (%), 2014
Figure 2-22: US - CNS Disorder Drugs in Phase-III by Disease (Number), 2014
Figure 2-23: US - CNS Disorder Drugs in Preregistration Phase by Disease (%), 2014
Figure 2-24: US - CNS Disorder Drugs in Preregistration Phase by Disease (Number), 2014
Figure 2-25: US - CNS Disorder Drugs in Registration Phase by Disease (%), 2014
Figure 2-26: US - CNS Disorder Drugs in Registration Phase by Disease (Number), 2014
Figure 2-27: US - Marketed CNS Disorder Drugs by Disease (%), 2014
Figure 2-28: US - Marketed CNS Disorder Drugs by Disease (Number), 2014
Figure 2-29: US - Alzheimer's Disease Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-30: US - Alzheimer's Disease Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-31: US - Multiple Sclerosis Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-32: US - Multiple Sclerosis Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-33: US - Parkinson's Disease Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-34: US - Parkinson's Disease Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-35: US - Neurodegenerative Disorders Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-36: US - Neurodegenerative Disorders Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-37: US - Epilepsy Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-38: US - Epilepsy Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-39: US - Migraine Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-40: US - Migraine Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-41: US - Huntington's Disease Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-42: US - Huntington's Disease Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-43: US - Neuropathic Pain Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-44: US - Neuropathic Pain Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-45: US - Schizophrenia Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-46: US - Schizophrenia Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-47: US - Sleep Disorders Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-48: US - Sleep Disorders Drugs Clinical Pipeline by Phase (Number), 2014
Figure 3-1: US - Alzheimer’s Disease Incidence (Million), 2013-2020
Figure 3-2: US - Multiple Sclerosis Incidence (‘000), 2013-2020
Figure 3-3: US - Epilepsy Incidence (Million), 2013-2020
Figure 3-4: US - Parkinson’s Disease Incidence (Million), 2013-2020
Figure 3-5: US - Migraine Incidence (Million), 2013-2020
Figure 3-6: US - Huntington’s Disease Incidence (‘000), 2013-2020
Figure 3-7: US - Schizophrenia Disease Incidence (Million), 2013-2020
Figure 3-8: US - Anxiety Disorder Incidence (Million), 2013-2020
Figure 3-9: US - Insomnia Incidence (Million), 2013-2020
Figure 3-10: US - Bipolar Disorder Incidence (Million), 2013-2020
Figure 3-11: US - ADHD Incidence (Million), 2013-2020

Note: Product cover images may vary from those shown
3 of 4
- Alkermes
- Allergan
- AstraZeneca
- Biogen Idec
- Bristol-Myers Squibb
- Eli Lilly
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Roche
- Sanofi
- Sunovion Pharmaceuticals
- Teva Pharmaceutical

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll